Dan Bloomfield, MD

Articles by Dan Bloomfield, MD

Abelacimab Shows Potential to Shift the Standard of Care in AFib

ByKyle Munz,Christian Ruff, MD,Dan Bloomfield, MD

February 11th 2025

Results from the AZALEA-TIMI 71 phase 2 trial showed great promise for abelacimab to transform care for high-risk patients with atrial fibrillation.

Atrial fibrillation | image credit: Uladzlislau - stock.adobe.com

Abelacimab, a “Game Changer” for High-Risk Patients With AFib: Dr Ruff and Dr Bloomfield Elaborate on Latest Data From AZALEA-TIMI 71 Trial

ByKyle Munz,Christian Ruff, MD,Dan Bloomfield, MD

January 22nd 2025

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients with atrial fibrillation (AFib).

Latest Updated Articles

Abelacimab, a “Game Changer” for High-Risk Patients With AFib: Dr Ruff and Dr Bloomfield Elaborate on Latest Data From AZALEA-TIMI 71 Trial
Published: January 22nd 2025 | Updated:

Dan Bloomfield, MD

Articles by Dan Bloomfield, MD

Abelacimab Shows Potential to Shift the Standard of Care in AFib

Abelacimab, a “Game Changer” for High-Risk Patients With AFib: Dr Ruff and Dr Bloomfield Elaborate on Latest Data From AZALEA-TIMI 71 Trial

Latest Updated Articles

Trending on AJMC

FDA Expands Evinacumab-dgnb Approval for Children as Young as 1 Year With HoFH

In Primary Care–Oncology Collaboration, the Baton Goes Both Ways

Trust and Transparency Key for Leveraging AI to Expand Access to Precision Oncology

Paltusotine FDA Approved for Acromegaly in Adults

Information and Integration Can Take Oncology Patients From Surviving to Thriving